Summary: The Financial Times explores how ketamine-assisted therapy is gaining popularity with business leaders and the workplace as a viable health benefit for employees.
MAPS Justice, Equity, Diversity and Inclusion Officer Steven Huang mentions, “Making psychedelic therapy an employee benefit ‘solves a lot of the issues’ that come with accessibility, affordability, and the stigma attached to psychedelics as a medical treatment.”
